Gynecological History in Chronic Fatigue Syndrome: A Population-Based Case-Control Study

Roumiana S. Boneva, M.D., Ph.D.1 Elizabeth M. Maloney, M.S., Dr.P.H.1 Jin-Mann Lin, Ph.D.1 James F. Jones, M.D.1 Friedrich Wieser, M.D.2 Urs M. Nater, Ph.D.1,3 Christine M. Heim, Ph.D.1,4 and William C. Reeves, M.D., M.Sc.1

Abstract

Background: Chronic fatigue syndrome (CFS) affects disproportionately more women than men, and the condition is more common at perimenopause. We examined gynecological history events as risk factors for CFS.

Methods: In a case-control study from a randomly selected population sample from Wichita, Kansas, 36 women with CFS and 48 nonfatigued controls, of similar age, race, and body mass index (BMI), answered a structured gynecological history questionnaire.

Results: CFS cases and controls had the same mean age (51 years) and age at menarche (12 years). Overall, a greater proportion of women with CFS than controls reported pelvic pain unrelated to menstruation (22.2% vs. 1.7%, \( p = 0.004 \)), endometriosis (36.1% vs. 16.7%, \( p = 0.046 \)), and periods of amenorrhea (53.9% vs. 46.2%, \( p = 0.06 \)). Compared to controls, women in the CFS group had a higher mean number of pregnancies (2.8 vs 2.0, \( p = 0.05 \)) and gynecological surgeries (1.8 vs. 1.1, \( p = 0.05 \)). Similar proportions of the CFS (69.4%) and control (72.9%) groups were menopausal. Although menopausal women in the CFS and control groups had similar mean age (55.5 and 55.8, respectively), menopause occurred about 4.4 years earlier in the CFS group (41.7 years vs. 46.1 years, respectively, \( p = 0.11 \)). Among menopausal women, 76% of the CFS group reported hysterectomy vs. 54.6% of controls (\( p = 0.09 \)), and 56% of women with CFS reported oophorectomy vs. 34.3% of controls (\( p = 0.11 \)).

Conclusions: The higher prevalence of gynecological conditions and gynecological surgeries in women with CFS highlights the importance of evaluating gynecological health in these patients and the need for more research to clarify the chronologic and the pathophysiological relationships between these conditions and CFS.

Introduction

Chronic fatigue syndrome (CFS) is a serious disabling illness, and about 70%–80% of people with CFS identified in both community-based and tertiary care-based case-control studies are women.1–3 The prevalence of CFS is highest in the 40–49-year-old age range.4 About 5% of women between 40 and 60 years of age in metropolitan, urban, and rural populations in central Georgia describe symptoms of CFS, and almost 3% of women in this age range meet strict clinical criteria for the illness.4–7 In spite of the preponderance of CFS in women of perimenopausal and menopausal ages, there is a paucity of literature about associations of gynecological factors with CFS.

There have been just a few research studies supporting a higher frequency of gynecological conditions in CFS. One study conducted in 1994 found that women with CFS (identified between 1989 and 1993 from physician practices in Atlanta, Georgia) were significantly more likely to have had a hysterectomy than were randomly selected age/race-matched community controls.8 Another study, conducted between September 1992 and December 1993, attempted to enroll all women between the ages of 21 and 73 who attended a Boston fatigue clinic between July 1984 and December 1993. They were retrospectively diagnosed with CFS by criteria of the 1988 CFS definition9 and were invited to participate in a case-control study; 51% completed a questionnaire on reproductive health. Controls were obtained among female outpatients of...
the Internal Medicine Department of the same hospital, and 66% completed the questionnaire. Women with CFS were more likely than controls to have reported a history of menstrual problems, galactorrhea, endometriosis, uterine fibroids, polycystic ovary syndrome, sexually transmitted diseases (STD) (including pelvic inflammatory disease [PID]), and cervical problems. The authors speculated that frequent anovulatory cycles associated with irregular menses and decreased progesterone, suggested by the high prevalence of polycystic ovary syndrome, contributed to an elevated estrogen/progesterone ratio among women with CFS, and that this caused chronic immune activation. There is a need to replicate these studies in a population-based case-control study design.

The present study sought to identify factors associated with CFS and generate a hypothesis by examining differences in gynecological history between women with CFS (cases) and well/nonfatigued controls randomly recruited from the population of Wichita, Kansas.

Materials and Methods

Subjects

This study adhered to U.S. Department of Health and Human Services (DHHS) human experimentation guidelines and received Institutional Review Board approval from the Centers for Disease Control and Prevention (CDC) and collaborating institutions. All participants gave informed consent. Data were collected during an in-hospital case-control study of persons with CFS and nonfatigued (NF) controls. In brief, the in-hospital study enrolled participants from the Wichita CFS Surveillance study conducted in 1997–2000. The Surveillance study used a random digit-dialing telephone survey to screen 56,146 adult residents 18–69 years of age in Wichita (Fig. 1). The telephone screening (in 1997) identified people who had fatigue for a month or more (n = 5295) and those who did not and was followed by a detailed telephone interview of those with fatigue (n = 3528 participants) and of 3634 randomly selected people without fatigue. That cohort of 7162 individuals was contacted for annual interviews between 1998 and 2000 (Fig. 1). All who met CFS criteria on the phone (CFS-like) were invited for a clinical evaluation along with: (1) a similar number of randomly selected nonfatigued persons matched to the CFS-like on age, sex, race, and body mass index (BMI) and (2) a random sample of persons with fatigue of ≥6 months but not meeting full CFS criteria (fatigued, unwell). The clinical evaluation included medical history, physical examination, laboratory tests, and psychiatric assessment and served to rule out exclusionary conditions and classify subjects as (1) CFS, (2) well, nonfatigued (NF) controls, and (3) persons with fatigue and some symptoms but not meeting full CFS criteria, named insufficient symptoms/fatigue (ISF). In 2002, the study concluded with a 2-day in-clinic evaluation in a Wichita research hospital unit. Invited for participation were 70 people classified as having CFS at any point during the 4-year Surveillance study (58, 83%, enrolled); 41 people with CFS and melancholic depression (27 enrolled); 70 NF controls matched to a person with CFS on sex, age, race, and BMI (55 enrolled); a random selection of 70 Surveillance participants who had unexplained fatigue for ≥6 months during the 4-year surveillance but who did not meet full CFS criteria (ISF) in the past (59, 84%, enrolled); and 39 people with ISF and melancholic depression (28 enrolled), that is, a total of 227 participants. On admission to the hospital, subjects underwent reevaluation of current CFS symptoms and exclusionary conditions (for a detailed description of the study and specifics of CFS and NF classification, see reference 7). Figure 1 shows the final distribution of participants. Only the 36 women with CFS and the 48 NF women (controls) are the subjects of comparison in this study.

Classification standards for CFS and control (NF)

Following exclusion of certain medical and psychiatric conditions, participants were classified as CFS or NF controls. We used criteria of the 1994 International CFS Research Case Definition, which were evaluated according to recommendations of the International CFS Study Group. Specifically, the study used internationally standardized, validated instruments to evaluate functional impairment (by the Short-Form Health Survey, [SF-36]), fatigue (by the Multi-dimensional Fatigue Inventory [MFI]), and frequency and severity of the eight CFS-defining symptoms (CDC Symptom Inventory). Classification as a current CFS case was based on cutoff scores derived from these rating scales with respect to the three-dimensional criteria of CFS specified in the case definition, that is, impairment, fatigue, and accompanying symptoms (for more details, see reference 7). Subjects meeting all three criteria at the time of the study were classified as CFS cases; those who met none of the criteria were classified as NF controls. Participants who met some but not all three criteria for CFS constituted the ISF, a separate group that is not included in the current analysis. Because invited controls were individually matched to cases with a CFS diagnosis during the past 4 years and subjects were reclassified according to current diagnostic status, strict matching could not be maintained. However, cases and controls were demographically similar.

Data collection

As part of the study’s in-hospital clinical evaluation, during the first day on the ward, all women completed a self-administered gynecological history questionnaire that queried age at menarche and menopause, duration of menstrual periods, bleeding between periods, cessation of periods for reason other than menopause, presence of lower abdominal/pelvic pain unrelated to menstruation, number of pregnancies, menopause, use of hormone replacement (yes or no), history of gynecological conditions, and surgeries. There were two separate questions for hysterectomy and for removal of ovaries (oophorectomy). Subjects were asked if they had had “other gynecological surgeries,” and if the answer was yes, the type of surgeries was queried. Questions about duration of menstrual period and bleeding between periods were answered only by premenopausal women. Physical examination in the clinic focused on identifying comorbidities exclusionary for CFS and did not include a pelvic examination. Review of medical records was not included in this study, as our major goals were to assess the prevalence of CFS in the community.

Statistical methods

Results are presented as mean and standard error of the mean (SEM) unless otherwise specified. We used the
chi-square test to compare distribution of dichotomous variables between the CFS and the control groups. To compare continuous variables, which were not normally distributed, we used the nonparametric Wilcoxon test. We used logistic regression to assess the magnitude of the association of CFS with dichotomous variables. Exact methods were used to calculate the 95% confidence intervals (CIs) for odds ratios (ORs) when cell sizes were small. We calculated two-sided p values to estimate the significance of associations. The statistical significance was set at alpha = 0.05. However, we report all p values and discuss all associations where the p value was <0.20 because such associations may be worth examining in future studies, as this was an exploratory analysis for hypothesis generating and because the study had a relatively small sample size, limiting its power to detect small-size effects. We used SAS 9.1 (Cary, NC) statistical software.

**Results**

Women with CFS were demographically similar to the controls (Table 1). Comparisons of gynecological history variables between the CFS and control groups are presented in Table 2. More than two thirds of cases and controls were menopausal (Table 2). The CFS and control groups did not differ in mean age at menarche (12 years), bleeding between periods, or mean duration of menstrual periods.

Amenorrhea, pelvic pain unrelated to menstruation, endometriosis, any gynecological surgery, and specifically hysterectomy and oophorectomy, were all more common in the CFS than in the control group. These differences between

---

**Table 1. Sample Characteristics of Women with Chronic Fatigue Syndrome and Controls, Wichita Case-Control Study of Chronic Fatigue Syndrome**

<table>
<thead>
<tr>
<th>Variable</th>
<th>CFS (n = 36)</th>
<th>Controls (n = 48)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>50.9 ± 1.5</td>
<td>51.2 ± 1.3</td>
<td>0.86</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td>0.21</td>
</tr>
<tr>
<td>White</td>
<td>33 (91.7)</td>
<td>47 (97.9)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1 (2.8)</td>
<td>1 (2.1)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>2 (5.5)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>29.5 ± 0.7</td>
<td>29.1 ± 0.7</td>
<td>0.68</td>
</tr>
</tbody>
</table>

*Mean ± standard error of the mean (SEM).

CFS, chronic fatigue syndrome.
CFS and controls were statistically significant for pelvic pain ($p = 0.004$), endometriosis ($p = 0.046$), and any gynecological surgery ($p = 0.045$) (Table 2). In addition, the CFS group had a significantly greater mean number of pregnancies (2.8 in CFS vs. 2.0 in controls, $p = 0.05$) and greater mean number of gynecological surgeries (1.7 in CFS vs. 1.1 in controls, $p = 0.05$). Menopause occurred on average 4 years earlier in the CFS group (~42 years vs. 46 years in controls), but this difference was not statistically significant ($p = 0.11$) (Table 2).

For the subset of women without a history of surgical menopause, however, the mean age at menopause was similar for the CFS and control groups (approximately 50 years) (table 2).

There was a strong association between endometriosis and pelvic pain (OR 15.3, 95% CI 2.4-158.4, $p = 0.0006$). In a multiple logistic regression model, including both variables as CFS cofactors, pelvic pain remained strongly and significantly associated with CFS (OR 10.05, 95% CI 1.1-91.73, $p = 0.04$), whereas endometriosis did not remain statistically significantly associated with CFS (OR 1.7, 95% CI 0.55-5.31, $p = 0.36$); however, these calculations are based on a small number of control women with pelvic pain.

Women with CFS were significantly more likely than controls to report any gynecological surgery (OR 2.96, $p < 0.05$). Overall, hysterectomy and oophorectomy were the most common surgeries. Among menopausal women with CFS, more than three quarters (76.0%) reported hysterectomy, and more than half (56.0%) reported oophorectomy. Menopausal women from the CFS group were more than twice as likely as menopausal controls to have had a hysterectomy (OR 2.67, $p = 0.05$).

### Table 2. Comparison of Gynecological History of Women with Chronic Fatigue Syndrome and Nonfatigued Controls

<table>
<thead>
<tr>
<th>Study group</th>
<th>CFS (n = 36)</th>
<th>Controls (n = 48)</th>
<th>OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gynecological variable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at menarche$^a$</td>
<td>12.3 ± 0.2</td>
<td>12.4 ± 0.2</td>
<td>ND</td>
<td>0.63</td>
</tr>
<tr>
<td>Duration of menstrual period ($n = 23$)$^b$</td>
<td>5.4 ± 0.4</td>
<td>5.0 ± 0.5</td>
<td>ND</td>
<td>0.55</td>
</tr>
<tr>
<td>Bleeding between periods$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1 (9.1)</td>
<td>1 (7.7)</td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>No ($n = 24$)$^d$</td>
<td>10 (90.9)</td>
<td>12 (92.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amenorrhea$^e$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21 (53.9)</td>
<td>18 (46.2)</td>
<td>2.33 (0.88-6.23)</td>
<td>0.06</td>
</tr>
<tr>
<td>No</td>
<td>15 (46.1)</td>
<td>30 (53.8)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Number of pregnancies/woman$^a$</td>
<td>2.8 ± 0.3</td>
<td>2.0 ± 0.2</td>
<td>ND</td>
<td>0.05</td>
</tr>
<tr>
<td>History of pelvic pain$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8 (22.2)</td>
<td>1 (1.7)</td>
<td>13.43 (1.61-608.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>No</td>
<td>28 (77.8)</td>
<td>47 (98.3)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>History of endometriosis$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13 (36.1)</td>
<td>8 (16.7)</td>
<td>2.83 (1.02-7.83)</td>
<td>0.046</td>
</tr>
<tr>
<td>No</td>
<td>23 (63.8)</td>
<td>40 (83.3)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Other gynecological conditions$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>12 (33.3)</td>
<td>8 (16.7)</td>
<td>2.50 (0.80-7.93)</td>
<td>0.078</td>
</tr>
<tr>
<td>No</td>
<td>24 (66.7)</td>
<td>40 (83.3)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Any gynecological surgery$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>28 (77.8)</td>
<td>26 (54.2)</td>
<td>2.96 (1.02-8.79)</td>
<td>0.045</td>
</tr>
<tr>
<td>No</td>
<td>8 (22.2)</td>
<td>22 (45.8)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Number of gynecological surgeries per person$^a$</td>
<td>1.75 ± 0.29</td>
<td>1.08 ± 0.20</td>
<td>ND</td>
<td>0.05</td>
</tr>
<tr>
<td>History of other gynecological surgery$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16 (44.4)</td>
<td>12 (25.0)</td>
<td>2.40 (0.86-6.75)</td>
<td>0.06</td>
</tr>
<tr>
<td>No</td>
<td>20 (55.6)</td>
<td>36 (75.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menopausal women$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age$^a$</td>
<td>55.6 ± 1.0</td>
<td>54.9 ± 1.1</td>
<td>ND</td>
<td>0.65</td>
</tr>
<tr>
<td>Age at menopause (years)$^a$</td>
<td>41.7 ± 2.3 ($n = 20$)</td>
<td>46.1 ± 1.5 ($n = 28$)</td>
<td>ND</td>
<td>0.11</td>
</tr>
<tr>
<td>Age at natural menopause</td>
<td>50.3 ± 1.5 ($n = 6$)</td>
<td>49.2 ± 1.6 ($n = 16$)</td>
<td>ND</td>
<td>0.68</td>
</tr>
<tr>
<td>Age at surgical menopause</td>
<td>31.9 ± 2.4 ($n = 14$)</td>
<td>38 ± 2.7 ($n = 12$)</td>
<td>ND</td>
<td>0.29</td>
</tr>
<tr>
<td>Duration of reproductive period$^a$</td>
<td>29.4 ± 2.2 ($n = 20$)</td>
<td>33.4 ± 1.5 ($n = 28$)</td>
<td>ND</td>
<td>0.13</td>
</tr>
<tr>
<td>Hysterectomy$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>19 (76)</td>
<td>19 (54.3)</td>
<td>2.67 (0.76-9.72)</td>
<td>0.09</td>
</tr>
<tr>
<td>No</td>
<td>6 (24)</td>
<td>16 (45.7)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Oophorectomy$^c$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>14 (56)</td>
<td>12 (34.3)</td>
<td>2.44 (0.75-8.06)</td>
<td>0.11</td>
</tr>
<tr>
<td>No</td>
<td>11 (44)</td>
<td>23 (65.7)</td>
<td>Reference</td>
<td></td>
</tr>
</tbody>
</table>

$^a$Mean ± SEM.

$^b$11 women with CFS and 12 controls.

$^c$n (%).

$^d$11 women with CFS and 13 controls.

$^e$Includes dilation and curettage (D&C), cesarean-sections, tubal ligations, and other.

CI, confidence interval; ND, net done; OR, odds ratio.
GYNECOLOGICAL HISTORY RISK FACTORS IN CFS

p = 0.09) or oophorectomy (OR 2.44, p = 0.11) (Table 2), but the association was not statistically significant. Finally, reporting oophorectomy was strongly associated with reporting of endometriosis (OR 12.00, 95% CI 3.24 - 44.42, p = 0.0002), and this was equally true for the CFS group (OR 11.25, 95% CI 1.65-76.84, p = 0.014) and for controls (OR 10.50, 95% CI 1.69-66.09, p = 0.012. In the overall sample of menopausal women (n = 60), the proportion of hormone replacement (HR) users in the CFS group (64%) and the control groups (57%) did not differ significantly (p = 0.79). Among menopausal women who reported hysterectomy with oophorectomy, reported HR in the CFS group (78.6%) was slightly lower compared with the control group (83.3%) but not statistically different.

Apart from hysterectomy and oophorectomy, other gynecological surgeries were also more frequently reported by women with CFS, with a higher mean number of these surgeries in the CFS group (0.83 ± 0.2 vs. 0.42 ± 0.13 in controls, p = 0.10). Of the other gynecological surgeries, dilation and curettage (D&C) was the most common procedure (19.4% of women with CFS and 4.2% of controls), followed by cesarean-section and tubal ligation. The most common reason for DCs in the CFS group was miscarriage: 11.1% of CFS subjects vs. 0% of controls (OR 2.50, 95% CI undefined, p = 0.03 by Fisher’s exact test). Among other gynecological diseases or abnormalities (reported by 33% of CFS and 17% of controls, p = 0.078), pelvic inflammation/infection was the most common condition and was more frequently reported by the CFS group than by controls, but the difference was not statistically significant (p = 0.22).

Discussion

Our study is one of very few to examine the association between female gynecological history and CFS. We found a strong association between CFS and history of pelvic pain unrelated to menstrual periods. Pelvic pain is a major symptom of endometriosis, and this could explain its association with both endometriosis and CFS. When both were included in the model, however, only pelvic pain remained significantly associated with CFS. Another plausible explanation of this association could be that lower abdominal/pelvic pain is also present in other conditions comorbid with CFS, such as interstitial cystitis and irritable bowel syndrome (IBS).

In our study, women with CFS were 2.8 times as likely as controls to report gynecological surgeries (OR 2.96, p < 0.05), particularly hysterectomy (OR 2.67, p = 0.09). Although not statistically significant, the association between hysterectomy and CFS in our study is in agreement with one previous case-control study from a physician-based CFS surveillance, which found a larger and statistically significant association between CFS and hysterectomy (OR 7.0, p < 0.05). Our results differ in that the magnitude of the association in that study by Reyes et al. was larger and the prevalence of hysterectomy, especially among controls, was lower (5%) than in our study. Hysterectomy has been associated with higher BMI. In our study, controls were approximately matched to CFS cases on BMI; thus, our control group might have been skewed toward higher risk of hysterectomy, resulting in a potential underestimate of the association between CFS and hysterectomy.

It is striking that 76% of menopausal women with CFS in our study reported hysterectomy. This high prevalence of hysterectomies may explain, at least partially, the observed earlier onset of menopause in the CFS group. The hysterectomy rate among controls in our study (39.6%) was comparable to the 34%–39% national and state data for similar age groups, supporting the reliability of our data. Our study seems to be only the second to find an association between hysterectomy and CFS, whereas in FM, a condition that shares many symptoms with CFS, the association with hysterectomy has been better documented. For example, Wagener et al. showed that 53% of women with FM had hysterectomy compared with 28% of control women with other rheumatologic or internal medicine diagnoses and that hysterectomy preceded the diagnosis of FM by an average of 4 years in approximately three quarters of women. Similarly, ter Borg et al. found a significantly higher prevalence of hysterectomies that preceded newly diagnosed FM (32.8% of cases) compared with controls with rheumatoid arthritis (14.6%), even though the control group was older. Finally, Pamuk et al. reported a higher frequency of hysterectomy and of early (age <45 years) menopause in women with FM compared with women of the same age who had rheumatoid arthritis. Taken together, these findings suggest a pathogenetic mechanism that could be related to the hormonal changes occurring after hysterectomy/oophorectomy or to the reason that led to hysterectomy. Women with CFS in our study were more than twice as likely...
as controls to have had oophorectomy. This association was not statistically significant (p = 0.11), but it deserves attention for hypothesis generation because bilateral oophorectomy (especially before onset of menopause) has been associated with various degenerative conditions, such as higher risk of cognitive impairment, neurological or mental diseases, unfavorable lipid profile, and cardiovascular disease. To elucidate the possible pathogenetic link between hysterectomy/oophorectomy and CFS, future larger studies should examine their chronological relationship.

Our findings and those reported in the literature associate CFS with higher prevalence of pelvic pain, amenorrhea, endometriosis, and gynecological surgeries. The mechanisms involved, as suggested in previous reports, may be estrogen/progesterone imbalance or deficiency. Harlow et al. speculated that frequent anovulatory cycles, associated with irregular menses and decreased progesterone (as suggested by the high prevalence of polycystic ovary syndrome in their study), contributed to a state of elevated estrogen/progesterone ratio among women with CFS. One study actually found a tendency for lower progesterone levels during the luteal phase and higher follicle-stimulating hormone (FSH) levels in premenopausal women with CFS compared with controls. In agreement with the hypothesis of hormonal imbalance (lower progesterone levels) in CFS, the reports on worsening of CFS symptoms around menopause [CFS Bulletin] or improvement with the addition of estrogen/progesterone.

Meaningful assessment of the relationship between CFS and female HR was not possible in our study because women were asked only about current HR but not when replacement started relative to menopause onset, what they took, or for how long. However, it is biologically plausible that low ovarian hormones may play some role in the pathogenesis of CFS in women because ovarian hormones can impact cognition, pain, mood, and numerous autonomic functions. Many of the symptoms typical for CFS, such as musculoskeletal pain, arthralgias, disturbed sleep, and cognitive impairment (“living in fog”), can be triggered by surgically (oophorectomy) or chemically induced menopause. We hypothesize that at any age, reduced or out of balance levels of gonadal hormones may contribute to the development of CFS symptoms through several known pathogenetic mechanisms: impaired sleep, loss of neuroprotective effects of progesterone and estradiol, increase in proinflammatory cytokines/upregulation of inflammation, possibly increased pain perception due to loss of estradiol’s and progesterone’s effects on antinociceptive pathways, and reduction of estrogen-facilitated and progesterone-facilitated healing and repair mechanisms.

Various reasons can lead to gradual or sudden decline in production of female sex hormones. Examples include premature ovarian failure, hysterosalpingo-oophorectomy (not followed by HR), reduced production of gonadotropins at the hypothalamo-pituitary level (via stress or disease), and iatrogenically induced reversible hypogonadism (via use of gonadotropin-releasing hormone [GnRH] analogues). Interestingly, a case of FM (a condition that shares many symptoms with CFS) has been reported to develop directly after treatment with GnRH analogue.

The hypothalamo-pituitary adrenal axis (and, especially, cortisol as a major stress hormone) has been relatively well studied in CFS. Early life stress and posttraumatic stress disorder (PTSD) have been found to be significant risk factors for CFS. Given that stress unfavorably affects the production of sex steroids via the hypothalamo-pituitary gonadal axis, the potential link between stress and gonadal steroid hormones in CFS may need to be explored in future research.

Interpretation of our findings should be considered in view of the study’s strengths and limitations. A major strength of the study is its design as a population-based case-control study, avoiding referral biases inherent to studies of CFS from referral clinics and the use of convenience controls. Nevertheless, the majority of the population in Wichita is white, and caution should be exercised in extrapolating conclusions to the entire U.S. population. However, our sample had basic gynecological health characteristics very similar to those from national data: mean age at menarche 12.4 vs. 12.7 years (from a study in three different states), mean number of pregnancies/woman 2.0 ± 0.2 vs. fertility rate of 2.1/ woman, and mean age at natural menopause 49.2 ± 1.6 years in our controls vs. means of 49.0 to 50.5 years in national data.

The study limitations include its relatively small sample size (with limited power to detect small effects as statistically significant), the limited number of questions (e.g., no questions on number of miscarriages and live births, on polycystic ovaries or infertility, and on age at hysterectomy), and self-reporting of conditions without review of medical records. The gynecological history was collected conveniently for examining its relationship to unexplained pelvic pain. No review of medical records was planned, as it was not feasible at this time and because exploring risk factors from the gynecological history was not a primary hypothesis in this study. Our findings are derived from a population-based study in which most patients with CFS reported gradual onset of symptoms and may not apply to women with sudden onset or postinfectious fatigue. Participants in this study were somewhat older than in other studies. A different participation rate between cases and controls may also have introduced selection bias. Nevertheless, our findings are consistent with the few studies examining relationships between CFS and gynecological history and with similar studies of FM.

In conclusion, the higher prevalence of gynecological conditions and surgeries in women with CFS highlights the importance of evaluating gynecological health in these patients. A thorough gynecological history should always be obtained in women with CFS or FM, and addressing gynecological problems and potential hormonal imbalances should be part of the overall care of women with CFS. The chronicological (and pathophysiological) relationship among endometriosis, hysteresectomy, and CFS remains to be examined in future, larger studies. Finally, it is obvious that not all women with the gynecological risk factors identified here develop CFS. Therefore, the interplay of potential genetic and environmental factors that affect gynecological function and health also needs to be examined in future CFS research. Better understanding of the various comorbidities and abnormalities associated with CFS (or subgrouping of the syndrome) could provide insights into its pathogenesis and, eventually, its prevention and treatment in affected women.

Acknowledgments

We acknowledge Elizabeth Unger, M.D., and Daisy Lee of the CDC and Suzanne Vernon, Ph.D., formerly of the CDC,
for their contributions to the study protocol and Marjorie Morrissey and Rebecca Devlin of Abt Associates for managing the study. We thank all women who volunteered to participate in the study. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the funding agency.

**Authors’ Disclaimer**

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

**Disclosure Statement**

The authors have no conflicts of interest.

**References**

22. www.scghecv.state.sc.us
23. www.scdhec.gov
34. Cevik R, Gur A, Acar S, Nas K, Sarac AJ. Hypothalamic-pituitary-gonadal axis hormones and cortisol in both menstrual phases of women with chronic fatigue syndrome and effect of depressive mood on these hormones. BMC Musculoskelet Disord 2004;5:47.

Address correspondence to:
Roumania S. Boneva, M.D., Ph.D.
Centers for Disease Control and Prevention
Mailstop A-15
1600 Clifton Road, NE
Atlanta, GA 30333
E-mail: rboneva@cdc.gov
This article has been cited by:


2. John W. Warren, Patricia Langenberg, Daniel J. Clauw. 2013. The number of existing functional somatic syndromes (FSSs) is an important risk factor for new, different FSSs. *Journal of Psychosomatic Research* 74, 12-17. [CrossRef]